IQV

IQVIA Wins Prestigious “Best AI-based Solution for Healthcare” Award in 2023 Artificial Intelligence Breakthrough Awards

Retrieved on: 
Tuesday, June 27, 2023
Health Technology, Data Management, Technology, Pharmaceutical, Professional Services, General Health, Medical Devices, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, Real, Natural language processing, Population health, IQVIA, North, Social, NLP, Organization, Patient, Head, Artificial intelligence, IQV, AI, NYSE, Medical device

IQVIA was recognized for its AI software, including natural language processing (NLP) technology, which analyzes complex and unstructured patient data to provide unique insight into patient care and disease states.

Key Points: 
  • IQVIA was recognized for its AI software, including natural language processing (NLP) technology, which analyzes complex and unstructured patient data to provide unique insight into patient care and disease states.
  • “Congratulations to IQVIA for delivering true breakthrough AI technology for the healthcare market.
  • IQVIA addresses this challenge head-on, providing a breakthrough AI-based solution already leading to improved patient outcomes.”
    “IQVIA is honored to receive this award and would like to thank AI Breakthrough for understanding the importance of this work,” said Benjamin Hughes, SVP Artificial Intelligence and Real World Data at IQVIA.
  • We’re committed to enabling the use of validated AI in healthcare for clinicians and data scientists.”

IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management

Retrieved on: 
Monday, June 26, 2023
Technology, Health Technology, Software, Practice Management, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Organization, IQV, Natural language processing, Ecosystem, Intelligence, NYSE, Safety, IQVIA, Global Safety Information Exchange, Medical device, Risk management

IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart Labeling , a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management.

Key Points: 
  • IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart Labeling , a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management.
  • RIM Smart Labeling is part of IQVIA’s suite of purpose-built regulatory, safety and quality technology solutions and services.
  • RIM Smart Labeling simplifies, automates and streamlines the global management of label changes through:
    Utilizing regulatory intelligence for implementation of global and country-specific labels, information translations and artwork
    Rather than using disparate systems, RIM Smart Labeling consolidates the activities into a single platform.
  • “IQVIA RIM Smart Labeling empowers organizations to streamline and standardize global label management across an increasingly intricate regulatory environment,” said Joe Rymsza, Vice President, Global Safety, Regulatory and Quality Technology Solutions at IQVIA.

IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening

Retrieved on: 
Thursday, May 25, 2023
Health Technology, Data Management, Technology, Pharmaceutical, Philanthropy, Fund Raising, Clinical Trials, Foundation, Science, Biotechnology, Software, AIDS, Other Science, Health, Research, Tuberculosis, Executive, Rockefeller Foundation, Global Public Health (journal), Partnership, Asylum, Migration and Integration Fund, The Global Fund to Fight AIDS, Tuberculosis and Malaria, IQVIA, Abbott, COVID-19, Infection, Global health, Mark R. Dybul, Pandemic, Investment, Laboratory, Bono, Bill, IQV, Diagnosis, Bill & Melinda Gates Foundation, Fund, Family, NYSE, RED, Pharmaceutical industry, Vaccine, Malaria

IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.

Key Points: 
  • IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.
  • The $5 million impact partnership will channel life-saving money to the Global Fund’s Laboratory Systems Integration Fund.
  • Doubling the impact, the Bill & Melinda Gates Foundation will match every dollar from the partnership to the Global Fund.
  • “Every day, IQVIA works alongside our customers and partners to help improve global health.

IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes

Retrieved on: 
Thursday, May 18, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Medical Devices, Research, Software, Science, Clinical Trials, IQVIA, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Failure, Senior, SEC Rule 144A, Debt-to-GDP ratio, Sale, Person, IQV, NYSE, Regulation, Security (finance), Note

IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the “Senior Secured Notes”) and $500,000,000 in aggregate principal amount of senior notes due 2030 (the “Senior Notes” and, together with the Senior Secured Notes, the “Notes”).

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the “Senior Secured Notes”) and $500,000,000 in aggregate principal amount of senior notes due 2030 (the “Senior Notes” and, together with the Senior Secured Notes, the “Notes”).
  • The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering.
  • The Senior Secured Notes will mature on May 15, 2028, unless earlier repurchased or redeemed in accordance with their terms.
  • The Senior Notes will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms.

IQVIA Announces Offering of Senior Secured Notes and Senior Notes

Retrieved on: 
Thursday, May 18, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Medical Devices, Research, Software, Science, Clinical Trials, SEC Rule 144A, IQV, IQVIA, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Failure, NYSE, Regulation, Sale, Person, Security (finance), Note

IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).

Key Points: 
  • IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).
  • The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering.
  • The consummation of the Notes offering is subject to market and other customary conditions.
  • Any offer of the Notes will be made only by means of a private offering memorandum.

IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award

Retrieved on: 
Thursday, May 11, 2023
Health Technology, Other Health, Pharmaceutical, Professional Services, General Health, Medical Devices, Women, Clinical Trials, Science, Biotechnology, DEI (Diversity, Equity and Inclusion), Consumer, Other Science, Health, Research, Rising Star, Woman, NYSE, HBA, Patient, IQV, Sheetal, Conference, Pharmaceutical industry, IQVIA

IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).

Key Points: 
  • IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).
  • Sheetal earned the award for her strong and innovative leadership, combined with her exemplary work in IQVIA’s clinical development business.
  • Sheetal has consistently been at the forefront of critical industry initiatives, such as reducing the burden for patients involved in clinical trials and increasing diversity and inclusion levels across clinical research.
  • "Sheetal's passion for clinical research and dedication to her role have made a significant impact on IQVIA and the industry,” said IQVIA Chairman and CEO Ari Bousbib.

IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance

Retrieved on: 
Thursday, April 27, 2023
Science, Other Science, Biotechnology, Research, Health, Health Technology, Clinical Trials, Other Health, RFP, Associated Press v. Meltwater U.S. Holdings, Inc., Share repurchase, Rising Medical Solutions, COVID, ID, DS, Sustainable Development Solutions Network, EBITDA, Webcast, IQV, Growth, EPS, R, Free cash flow, Adjustment, TAS, NYSE, Music, Cryptocurrency, IQVIA

As of March 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $27.9 billion, growing 10.1 percent year-over-year and 11.3 percent at constant currency.

Key Points: 
  • As of March 31, 2023, R&DS contracted backlog, including reimbursed expenses, was $27.9 billion, growing 10.1 percent year-over-year and 11.3 percent at constant currency.
  • "IQVIA delivered another quarter of strong operational and financial results, including strong underlying revenue growth, margins and cashflow," said Ari Bousbib, chairman and CEO of IQVIA.
  • All financial guidance assumes foreign currency exchange rates as of April 25, 2023 remain in effect for the forecast period.
  • IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its first-quarter 2023 results and its second-quarter and full-year 2023 guidance.

IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023

Retrieved on: 
Thursday, April 20, 2023
Technology, Research, Professional Services, Software, Biotechnology, Health, Data Analytics, Data Management, Science, IQV, NYSE, OCE, Salesforce, Environment, CXP, IQVIA, Fine chemical

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement ( OCE ) platform.

Key Points: 
  • IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement ( OCE ) platform.
  • The IQVIA OCE platform was recognized as a Leader in the CXP pharma provider sector for its well-rounded portfolio of industry-leading products, which offer the ability to drive better customer engagement.
  • “We’re pleased that Everest Group recognizes IQVIA as an industry Leader for the OCE platform, which enhances the customer experience for our clients,” said Sanjay Chikarmane, Chief Product Officer, IQVIA.
  • “Customers consider its experience with large biopharma companies and ability to share industry best practices as a differentiator, hence earning its Leader position.”
    To review the complete report, including details on IQVIA’s leader status, please click here .

IQVIA to Announce First-Quarter 2023 Results on April 27, 2023

Retrieved on: 
Thursday, April 6, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Medical Devices, Research, Software, Science, Clinical Trials, Webcast, IQV, IQVIA, Wright Investors' Service Holdings, Inc., NYSE, ID

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023.
  • The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day.
  • The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com .

IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023

Retrieved on: 
Wednesday, March 1, 2023
Technology, Other Technology, Clinical Trials, Biotechnology, Networks, Other Health, Health, General Health, Data Management, IQV, Webcast, NYSE, IQVIA, Information Holdings Inc., Conference, Cryptocurrency, Broadcasting

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m.
  • ET.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • A replay of the webcast will be available later that day.